Xifaxan Treatment for IBS-C

Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder. The exact reason for the disease is unknown and may be a combination of multiple factors. IBS causes several symptoms such as a change in bowel habits, cramping, abdominal pain, an intolerance to food, and distention. A diagnosis of IBS is based on the duration of at least six months, and a frequency of signs and symptoms (mentioned above) which occur at least three times a month. There are two types of IBS. IBS-D (IBS with diarrhea) is characterized by continuous or recurrent diarrhea. IBS-C is characterized by constipation and abdominal pain. Treatment includes dietary modifications, lifestyle changes, and prescription medications (on the recommendation of a doctor).


Medicine can help relieve and manage symptoms on a temporary basis, allowing those suffering from IBS to live normally. There is no known cure for the disease yet. Treatment includes dietary modifications, lifestyle changes, and prescription medications. The selection of pharmacologic treatments remains symptom-directed as there are different medications to treat different symptoms. Maintain a healthy diet and eat food with fiber (if constipated) to avoid the possibility of anything worse in the future.

Rifaximin (Xifaxan)

Rifaximin is a medicine which must be taken for 14 days. This medicine is helpful for those suffering from IBS-D (irritable bowel syndrome with diarrhea) and experiencing symptoms such as chronic, or repeated diarrhea, and distention (bloating). If a recurrence of IBS occurs, patients are once again given a course of medicines to take over a period of 14 days. The medicine is generally effective for periods of up to 10 days after completing its course of intake. Rifaximin is minimally absorbed and stays in the gut. It is, therefore, preferred over antibiotics. Stop using rifaximin and call your doctor at once if you have a fever or diarrhea that is watery or bloody. This medication may be able to treat constipation as well.

Featured Image: Twitter

Posted on May 5, 2023